Aravive, Inc. (ARAV) 10-Q Quarterly Report Wed May 06 2020

HOUSTON, May 6, 2020 – Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the first quarter ended March 31, 2020.

“The first quarter of 2020 marked an important period for Aravive, as demonstrated by the accomplishment of several key events, including the publication of encouraging preclinical findings supporting the advancement of our lead product candidate, AVB-500 in abstracts for the Society for Gynecologic Oncology 2020 Annual Meeting,” said Gail McIntyre, Ph.D., chief executive officer of Aravive. “Patient safety and trial integrity remain our top priorities as we continue to closely monitor the potential impact of COVID-19 to our ongoing programs and we are on schedule to have safety, pharmacokinetic and preliminary efficacy data from our Phase 1b platinum-resistant ovarian cancer study mid-2020. Looking ahead, the remainder of 2020 will be an important time for Aravive as we responsibly navigate the current global environment, enroll more patients into clinical trials and make progress towards changing the treatment paradigm for patients with cancer.”

Recent Corporate Updates

•

Formed Strategic Collaboration with WuXi Biologics to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis: In April 2020, Aravive and WuXi Biologics announced that they are collaborating to develop novel high-affinity bispecific antibodies against CCN2, also known as connective tissue growth factor (CTGF), implicated in cancer and fibrosis and identified from a similar target discovery screen that identified the significance of the AXL/GAS6 pathway in cancer.

•

Announced Board Composition and Executive Management Transitions: In April 2020, Aravive announced the promotion of Gail McIntyre, Ph.D., from chief scientific officer to chief executive officer and her appointment to the board of directors. In addition, Aravive announced changes to its board of directors with the appointment of healthcare entrepreneur, Dr. Fred Eshelman, Pharm.D. as chairman and the resignations of Jay Shepard, Srinivas Akkaraju, M.D., Ph.D., Robert Hoffman and Rekha Hemrajani.

The following information was filed by Aravive, Inc. (ARAV) on Wednesday, May 6, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1513818/000156459020021944/arav-10q_20200331.htm

View differences made from one quarter to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aravive, Inc..

Continue

Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Financial

Other

Filter by Subcategory:

All

Expense

Income

Cash Flow

Other

Inside Aravive, Inc.'s 10-Q Quarterly Report:

Financial - Expense Highlight
General and administrative expense General and administrative expense decreased by $0.6 million, or 14%, to $3.9 million for the three months ended March 31, 2020 from $4.6 million for the same period in 2019.

Financial - Expense Highlight
Internal research and development costs consist primarily of salaries and related fringe benefit costs for our employees (such as workers' compensation and health insurance premiums), stock-based compensation charges and travel costs.
Financial - Income Highlight
Interest income Interest income decreased primarily due to cash balances being used to fund operations and lower interest rates in the three months ended March 31, 2020 as compared to the three months ended March 31, 2019.
Other - Other Highlight
Cash used in operating activities in for the three months ended March 31, 2020 increased significantly compared to the same period in 2019 due the ramp up in clinical trials along with beginning the treatment of our second oncology indication, ccRCC and was offset by the receipt of CPRIT Grant funds of approximately $1.6 million.
Other - Other Highlight
Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled "Risk Factors" included under Part II, Item 1A below and those identified under Part 1, Item 1A of the Annual Report.
Other - Other
We believe, based on our...Read more
Other - Other
While we are experiencing limited...Read more
Other - Other
At March 31, 2020, we...Read more
Other - Other
Given the uncertainty of the...Read more
Financial - Shares
Since our inception and through...Read more
Financial - Expense
The increase in the three...Read more
Other - Other
Importantly, AVB-500 had a favorable...Read more
Financial - Cash Flow
If such assets are considered...Read more
Other - Other
Cash provided by financing activities...Read more
Other - Other
If the COVID-19 pandemic continues...Read more
Financial - Cash Flow
Based on the undiscounted cash...Read more
Financial - Expense
Other (expense) income, net Other...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Aravive, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ARAV
CIK: 1513818
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-021944
Submitted to the SEC: Wed May 06 2020 4:16:46 PM EST
Accepted by the SEC: Wed May 06 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations